They are a newly organized blank check company. While they may pursue an acquisition opportunity in any business, industry, sector or geographical location, they intend to focus on industries that complement their management team’s background, and to capitalize on the ability of their management team to identify and acquire a business, focusing on the healthcare or healthcare related industries in the United States and Europe. In particular, they intend to prioritize companies in the life sciences sector where their management team has extensive experience. Joining their company is a team of high-level senior life sciences executives. The team includes Brian Atwood, who will serve as their Chairman immediately upon the effective date of this prospectus, Chris Ehrlich, their Chief Executive Officer, Douglas Fisher, MD, their President, and Daniel Geffken, their Chief Financial Officer. Their Board of Directors is expected to provide valuable guidance, technical domain expertise, value-added input regarding senior team leadership capabilities of prospective business combination targets, and have access to differentiated ideas and opportunities through complementary networks. They also have specific special purpose acquisition company, or SPAC, experience and a proven track record of business combination success.